Board of Directors

Matt Trerotola has spent most of his career in various roles at DuPont, Danaher Corporation, and McKinsey & Company. Prior to joining Enovis (Colfax at the time) where he served as a director of the Company since July 2015, Mr. Trerotola was an executive vice president at DuPont. At DuPont, he was responsible for $6.3 billion of revenue in safety and protection and electronic materials, along with overall corporate responsibility for Asia. At Danaher, he held several leadership positions from 2007 to 2013, including serving as Vice President and Group Executive for the $2.5 billion life sciences platform. Before that, he progressed from President of Videojet, a subsidiary of Danaher, to Group Executive for product identification. In these roles, he strengthened talent, greatly accelerated organic growth, improved profitability, and made strategic acquisitions. Mr. Trerotola received a Bachelor of Science degree in chemical engineering from the University of Virginia in 1989 and an MBA from Harvard Business School in 1995. Mr. Trerotola currently serves on the board of directors of AptarGroup, Inc. (NYSE: ATR).

Brady Shirley currently serves the Company in the role of Executive Advisor, leveraging his deep industry knowledge and significant leadership experience to support our management team in planning and executing our strategic initiatives. Prior to his service as Executive Advisor, Mr. Shirley served as President and Chief Operating Officer of Enovis, having formerly served as Chief Executive Officer of DJO Global. Mr. Shirley joined DJO in 2014 as President of the DJO Surgical business and helped establish it as one of the best growth engines in the reconstructive market. He was appointed CEO in 2016 and led the transaction into Colfax, now Enovis, in 2019. From 2009 to 2013, Mr. Shirley was the CEO and a Director of Innovative Medical Device Solutions (IMDS), an orthopedic outsource development and manufacturing company. At IMDS, he managed the integration of four companies, consolidated the capital structure, and led a successful sale of the business in 2013. From December 1992 to August 2009, he held several key leadership positions with Stryker Corporation, including President of Stryker Communications and Senior Vice President of Stryker Endoscopy.

Liam J. Kelly has served as a director of the Company since January 1, 2020. Mr. Kelly has served as the Chairman, President and Chief Executive Officer of Teleflex Incorporated, a global provider of medical technology products, since May 1, 2020. Prior to that, Mr. Kelly held the office of President and Chief Executive Officer since January 1, 2018. Since joining Teleflex in 2009, Mr. Kelly has held a variety of senior leadership roles. From May 2016 to December 2017, Mr. Kelly served as Teleflex’s President and Chief Operating Officer and from April 2015 to April 2016, he served as Executive Vice President and Chief Operating Officer. Prior to joining Teleflex, Mr. Kelly held various senior level positions with Hill-Rom Holdings, Inc., a medical device company, from October 2002 to April 2009, serving as its Vice President of International Marketing and R&D from August 2006 to February 2009.

Philip Okala has served as a director of the Company since February 22, 2021. He currently serves as system president at City of Hope, one of the largest cancer research and treatment organizations in the United States, where he is responsible for City of Hope’s portfolio of clinical care and research entities. Mr. Okala was previously the Chief Operating Officer (COO) of the University of Pennsylvania Health System, a network of leading hospitals and associated care facilities serving Philadelphia County and the surrounding area. Prior to his COO role, Mr. Okala held various positions with Penn Medicine since 2007, including serving as Senior Vice President for Strategy and Business Development from 2013 to 2017. Before joining Penn Medicine, Mr. Okala held various positions with other healthcare organizations including System Vice President of the Cancer Service Line at Geisinger Health System, Vice President for Clinical Strategic Planning at Roswell Park Cancer Institute and management positions at the University of Texas MD Anderson Cancer Center. He is a Fellow in the American College of Healthcare Executives (FACHE), a Fellow with Healthcare Financial Management Association, and currently serves on the board of the Holy Child School at Rosemont.

A. Clayton Perfall has served as a director of the Company since September 21, 2010. Previously, he served as an Operating Executive of Tailwind Capital, a private equity fund manager focused on growing middle market companies in the Healthcare, Technology, Business Services and Industrial services sectors from 2014 through 2022. He served as the Chairman and Chief Executive Officer of Archway Marketing Services, Inc., a provider of marketing logistics and fulfillment services, from 2008 through 2013. From 2001 until 2008 Mr. Perfall served as the Chief Executive Officer and as a member of the board of directors of AHL Services, Inc. Mr. Perfall also served as the Chief Executive Officer of Union Street Acquisition Corp. from 2006 until 2008. He served as the Chief Financial Officer of Snyder Communications, Inc. from 1996 until 2000 and was previously a partner with a large international accounting firm. Mr. Perfall currently serves on the board of directors of the private company Distinct Holdings Group, LLC and previously served on the boards of directors of Comstock Holding Companies, Inc. from 2004 to 2018, Tailwind Premier Holdings, LLC, from 2015 until 2019 Archway Marketing Services, Inc. from 2008 until 2013, RT Acquisition Corp. from 2012 until 2015 and inVentiv Health, Inc. from 1999 to 2010. He served as the audit committee chairman for Comstock Holding Companies, Inc. and inVentiv Health during his time on those boards. Mr. Perfall’s significant financial expertise and experience as an audit committee chairman and public company Chief Financial Officer, combined with his substantial executive leadership background, are assets to both our Board and our Audit Committee.

Rajiv Vinnakota has served as a director of the Company since May 13, 2008. Since July 2019, he has served as the President of the Institute for Citizens & Scholars (formerly the Woodrow Wilson National Fellowship Foundation), a 75 year-old non-profit organization that played a significant role in shaping higher education. With an expanded mission, Citizens & Scholars is now rebuilding how we develop citizens in our country. From 2015 to September 2018 he served as Executive Vice-President at the Aspen Institute, leading a division focused on youth and engagement. Prior to this role, Mr. Vinnakota was the Co-Founder and Chief Executive Officer of The SEED Foundation, a non-profit educational organization, at which he served from 1997 to 2015. Mr. Vinnakota was the chairman of The SEED Foundation board from 1997 until 2005. Prior to co-founding SEED, Mr. Vinnakota was an associate at Mercer Management Consulting. He was also a trustee of Princeton University from 2004 until 2007 and a member of the Executive Committee of the Princeton University board of directors from 2006 to 2007, and he served as the national chairman of Annual Giving at Princeton from 2007 until 2009. Mr. Vinnakota currently serves as a director of ESAB Corporation.

Sharon Wienbar has served as a director of the Company since June 15, 2016. She was previously with Scale Venture Partners, a venture capital firm, from 2001 to 2018, where she led investments in technology companies and served on the board of numerous portfolio businesses. She was also a strategy consultant to Capella Education Company after it acquired Hackbright Academy, a leading software engineering training company for women, where she was the CEO from 2015 to 2016. Ms. Wienbar currently serves on the boards of Resideo Technology, a New York Stock Exchange-listed public company, True Anthem, a privately held software provider, and Kaleido Health, a leading women’s health app. She previously served on other public and private boards, including Covetrus, Inc., a Nasdaq listed public company, until its acquisition in October 2022, the board of Everyday Health, Inc., a New York Stock Exchange-listed public company, until its acquisition in December 2016. Prior to her venture capital career, Ms. Wienbar was an executive in several software companies and a consultant at Bain & Company. Ms. Wienbar’s leadership of technology investments, deep understanding of innovation drivers, and business acumen bring an important perspective to our Board.

Dr. Ortiz is the Morris Cohen Professor of Materials Science and Engineering at the Massachusetts Institute of Technology where she has made pioneering advancements in the areas of biotechnology, biomaterials, and nanotechnology. The author of more than 200 scholarly publications, she has supervised research projects across multiple academic disciplines, received 30 national and international honors, including the Presidential Early Career Award in Science and Engineering awarded to her by President George W. Bush, and served as the Dean for Graduate Education at MIT from 2010 to 2016. She is the founder of an innovative, nonprofit, post-secondary educational institution, Station1. Dr. Ortiz earned a Bachelor of Science degree from Rensselaer Polytechnic Institute and a Master of Science degree and a Doctor of Philosophy degree from Cornell University, each in the field of materials science and engineering. She also serves as a director of Mueller Water Products (NYSE: MWA), a publicly traded water infrastructure and technology company. At Enovis, Dr. Ortiz serves as a member of the Nominating and Corporate Governance Committee of the Board.

Ms. Lalor served as Senior Vice President, Human Resources, of Danaher Corporation from 2012 until April 1, 2022, when she moved into an advisory role with Danaher until her retirement from Danaher at the end of the first quarter of 2023. Prior to her career at Danaher, Ms. Lalor served at 3M for 22 years in a series of roles of progressive responsibility, including her final role as Senior Vice President of Human Resources for the company. Ms. Lalor holds a B.A. in Psychology from University of Northern Iowa and an M.A. in Industrial Relations and Human Resources from the University of Iowa. Ms. Lalor serves as Chair of the Compensation and Human Capital Management Committee of the Board.

Ms. Bodem served as Interim Chief Financial Officer at Dentsply Sirona Inc., from April of 2022 to October 2022. She previously served as Senior Vice President and Chief Financial Officer at Hillrom, a global medical technology company, from 2018 until its acquisition by Baxter International Inc. (NYSE: BAX) in 2021, and as the Senior Vice President of Finance at Mallinckrodt Pharmaceuticals, a pharmaceutical manufacturer, from 2015 to 2018. Ms. Bodem has also served in senior finance roles for Hospira, Inc. and Eli Lilly & Company. She currently serves as a director of Syneos Health, Inc., (Nasdaq: SYNH), an integrated biopharmaceutical solutions company, where she is a member of the audit committee. Ms. Bodem received both her Bachelor of Science in Finance and MBA from Indiana University. Ms. Bodem serves as a member of the Audit Committee of the Board.